1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” This study discusses two cases of acneiform skin eruptions associated with the use of the EGFR inhibitor ZD1839 in prostate cancer treatment, emphasizing the need for dermatologists to be aware of potential skin reactions.
June 2026 in “Frontiers in Oncology” In this study, researchers found that deficiencies in Gsdma1/2/3 significantly inhibited the initiation and progression of cutaneous squamous cell carcinoma (cSCC) in mice, suggesting GSDMA's role in promoting cSCC proliferation and its potential as a therapeutic target.
June 2026 in “British Journal of Dermatology” In this case report, researchers observed a Slovakian neonate with a rare EGFR genetic mutation who presented with severe neonatal dermatoses, ichthyosis, and multisystem complications, emphasizing the significance of genetic diagnosis for such complex conditions.
April 2026 in “International Journal of Clinical Oncology” This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.
February 2026 in “International Journal of Molecular Sciences” In this study, Lrig1-positive stem cells in mouse hair follicles were found to be essential for sebaceous gland formation and maintenance, with their depletion causing a temporary loss of these glands and changes in cellular differentiation.
January 2026 in “Medicine” This study suggests that Hejie Shengfa Decoction may help treat alopecia areata by influencing immune and inflammatory pathways, regulating apoptosis, and enhancing the follicular microenvironment.
January 2026 in “Scientific Reports” In this study, researchers found that sesamin, a component of sesamum, modulated the AR-MAPK-Wnt signaling pathway in DHT-stimulated HaCaT keratinocytes, demonstrating potential multi-target activity against molecular events in androgenetic alopecia.
This study investigated the mechanisms of Platycladi Cacumen in treating androgenetic alopecia, identifying potential key components and targets but found no specific targets or regulatory mechanisms.
December 2025 in “Biomedicines” This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.
This study mapped potential targets and pathways for baicalin's action in androgenic alopecia, suggesting it may inhibit 5α-reductase and serve as an effective treatment ingredient.
September 2025 in “Stem Cells Translational Medicine” This study found that exosomes from human umbilical cord stem cells, pretreated with lithium chloride, significantly enhance hair regeneration in mice by activating the Wnt signaling pathway through miR-146a-5p.
June 2025 in “British Journal of Clinical Pharmacology” This study highlights the significant impact of cutaneous side effects associated with anticancer therapies, emphasizing the need for proactive management to improve patient quality of life and treatment adherence.
This case study documents a 55-year-old male with advanced NSCLC who experienced toe-predominant paronychia and a papulopustular rash following dacomitinib treatment, with the causality tools indicating a "probable" link, yet the therapy continued successfully without dosage alteration.
May 2025 in “Dermatology Online Journal” This report describes a rare case of eyelash overgrowth and eyelid irritation in a woman treated with erlotinib for lung adenocarcinoma, highlighting a potential side effect of the drug.
May 2025 in “Experimental Dermatology” This study found that specific TRPM5 modulators are unlikely to directly affect sebaceous glands, but safe TPPO analogues may provide moderate lipogenic and anti-inflammatory effects beneficial for dry skin conditions.
December 2024 in “Frontiers in Genetics” This review discusses the genetic causes and pathogenesis of Olmsted syndrome, emphasizing the potential for a genotype-phenotype correlation due to TRPV3 mutations, and explores avenues for individualized treatment developments for this condition.
November 2024 in “Journal of Cosmetic Dermatology” This study observed that a topical serum containing Silybum marianum extract, manganese PCA, and Lespedeza capitata extract enhanced hair follicle growth and hair shaft elongation, while prolonging the anagen phase in an ex vivo human scalp skin model, suggesting potential benefits for hair loss treatment.
November 2024 in “EMBO Molecular Medicine” This study used a mouse model to enhance understanding of alopecia pathogenesis and suggested a therapeutic strategy for managing inflammation in EGFR-inhibitor therapy-induced folliculitis and cicatricial alopecia.
November 2024 in “NeoReviews” This case report details an extremely low-birth-weight preterm neonate presenting with unique dermatologic symptoms, leading to a diagnosis of neonatal inflammatory skin and bowel disease due to a novel homozygous EGFR gene mutation, highlighting the importance of genetic testing in ambiguous cases.
June 2024 in “Research Square (Research Square)” This study found that among young women in West Bengal, India, co-occurring PCOS and related conditions like estrogen resistance and leptin receptor insufficiency are common, with notable genetic variations identified, including impairments in leptin signaling and insulin resistance.
April 2024 in “Journal of pharmacy & pharmacognosy research” This study used in silico analysis to identify 4-[2-(4-nitrophenyl)ethylcarbamoyl]benzenesulfonyl as a potential inhibitor of the EGFR mutant associated with NSCLC, highlighting the need for further in vitro and in vivo validation.
January 2024 in “Journal of dermatology and skin science” In this study, researchers found that applying topical aprepitant, which blocks substance P receptors, significantly reduced facial dermatitis and hair loss in rats experiencing erlotinib-induced skin side effects, highlighting the neurogenic inflammation's role and the protective effect of ROS inhibition.
November 2023 in “Biology” This study investigated m6A RNA modification in hair follicle development, finding that Hycole rabbits displayed longer hair, higher primary hair follicle ratios, and thicker skin compared to Rex rabbits, while also identifying key differential genes and pathways involved in hair growth.
This research observed that EGFR activity appears to maintain hair follicle quiescence and immune privilege, and its inhibition may lead to stem cell apoptosis and scarring alopecia during inflammation.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” This study reported that in mouse models, deletion of EGFR resulted in stem cell hyper-proliferation followed by apoptosis, leading to scarring alopecia, and implicated EGFR's role in maintaining hair follicle quiescence and immune privilege during inflammation.
April 2023 in “Journal of Investigative Dermatology” In this study using a mouse model of Pemphigus vulgaris, researchers found that loss of desmoglein 3 adhesion in hair follicle stem cells triggers a regenerative program restoring stem cell function, requiring Hedgehog pathway suppression.
In this study, the combined treatment of ursolic acid and resveratrol was evaluated for its effects on skin tumor promotion in female FVB mice. The combination was applied topically before TPA treatment and was found to significantly inhibit TPA-induced epidermal hyperproliferation, signaling pathways, and skin inflammation more effectively than either compound alone. Key signaling pathways affected included EGFR, STAT3, and NF-κB, among others. The combination also increased tumor suppressor levels and reduced proinflammatory cytokine expression. Overall, the combined treatment resulted in a greater reduction in tumor multiplicity and size, highlighting its potential as a more effective strategy for inhibiting skin tumor promotion compared to individual treatments.
In this study, the combined treatment of ursolic acid and resveratrol was evaluated for its inhibitory effects on skin tumor promotion in female FVB mice. The combination was applied topically before TPA treatment and was found to significantly inhibit TPA-induced epidermal hyperproliferation, signaling pathways, and skin inflammation more effectively than either compound alone. Key signaling pathways affected included EGFR, STAT3, and NF-κB, among others. The combination also increased tumor suppressor levels and reduced proinflammatory cytokine expression. Overall, the combined treatment resulted in a greater reduction in tumor multiplicity and size, highlighting its potential as a more effective strategy for preventing skin tumor promotion compared to individual treatments.
This study found that neutrophil-rich hair follicle inflammation caused by a monoclonal antibody targeting murine EGFR in mice involved TNFα and interleukin-1, suggesting these cytokines play a role in EGFR antibody-induced rashes in cancer patients.
This study in mice found that a monoclonal antibody targeting EGFR resulted in skin inflammation mediated by TNFα, suggesting potential pathways for addressing EGFR antibody-induced skin rash in cancer patients.